BioNTech Results Presentation Deck
Selected 2022 Pipeline Milestones
COVID-19 vaccine:
Follow on and Next
Gen Vaccines
4 Infectious Disease
First-In-Human
Trial Starts
4 Oncology First-in-
Human Trial Starts
30
3 Data Updates
Milestones
Omicron BA.4/5-adapted bivalent vaccine trial start
BNT162b5: Next-generation bivalent vaccine, enhanced SARS-CoV-2 encoding ancestral and
BA.2 spike antigen
T cell enhancing vaccine trial start
Additional next-generation vaccine trial starts, including pan-SARS-CoV-2 vaccine
Multiple data updates
Shingles vaccine ¹
BNT163 HSV2 vaccine
BNT164 tuberculosis vaccine²
BNT 165 malaria vaccine
BNT141 RiboMab in solid tumors (CLDN18.2)
BNT142 RiboMab in solid tumors (CD3×CLDN6)
BNT116 FixVac in combo with Cemiplimab in NSCLC
BNT313 (GEN1053) in solid tumors³
BNT 161 influenza mRNA vaccine ¹
BNT1224 Phase 2 iNeST in combo with Pembro in frontline melanoma
BNT211 Phase 1/2 CAR-T/CLDN6+ in multiple solid tumors
HSV 2, Herpes simplex virus type 2; FPD, first patient dosed; CLDN, Claudin; NSCLC, non-small cell lung cancer
1 Partnered with Pfizer; 2 Collaboration with BMGF; 3 Collaboration with Genmab 4 Partnered with Genentech
Anticipated Timing
August 2022
Phase 2: FPD
July 2022
2H 2022
2H 2022
2H 2022
2H 2022
2H 2022
2H 2022 / early 2023
2H 2022 / early 2023
FPD in Jan. 2022
FPD in July 2022
FPD in July 2022
2H 2022
July 2022
now in 1H 2023
2H 2022
BIONTECHView entire presentation